ArticleNeurology(R) neuroimmunology & neuroinflammation2025
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Antibody-Dependent Cellular Phagocytosis and Cytotoxicity in Patients With LGI1 and CASPR2 Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Diagnosing autoimmune encephalitis in psychiatry: clinical recommendations and unresolved challenges from the GENERATE network.Molecular psychiatry · 2026Review
- Current and Future Biomarkers in the Diagnosis of Autoimmune Encephalitis: A Review of Biomarker Detection Techniques and Their Performance.Medicina (Kaunas, Lithuania) · 2026Review
- Detection of neural autoantibodies in dogs with non-infectious inflammatory central nervous system disorders.Journal of veterinary internal medicine · 2026Article
- Neuronal autoantibodies in neurodegenerative dementia: From evidence to clinical framework.The journal of prevention of Alzheimer's disease · 2026Review
- Testing for neural antibodies in autoimmune encephalitis: who, what, where, when, why, and how.Therapeutic advances in neurological disorders · 2026Review
- Differential Diagnosis of Infectious Versus Autoimmune Encephalitis Using Artificial Intelligence-Based Modeling.Journal of clinical medicine · 2025Article
- Autoimmune neuropsychiatric disorders manifesting with psychosis.The Journal of clinical investigation · 2025Review
- Article
- Beyond the Lab Slip: Why Laboratory Expertise Matters in Neuronal Antibody Testing and Why Clinicians Should Care.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDetecting neural surface antibodies (NSAbs) is essential for diagnosing autoimmune encephalitis. The recommended diagnostic strategy involves initial screening with tissue-based assays (TBAs), followed by confirmation with cell-based assays (CBAs). While specialized centers use in-house TBAs, many clinical laboratories depend on commercial TBAs, whose accuracy is yet to be fully assessed.
methodsWe selected 92 CSF and 99 serum samples from patients with autoimmune encephalitis and NSAbs confirmed by in-house TBAs and CBAs (20 samples each for AMPAR, GABA
resultsThe experienced raters agreed on 94% (133/142) of CSF and 88% (131/149) of serum classifications (Cohen's kappa = 0.87 and 0.75, respectively, DISCUSSION: The diagnostic performance of EUROIMMUN IIF-TBA in detecting NSAbs in autoimmune encephalitis is suboptimal. NMDAR antibodies, among the most common NSAbs, can be missed in 50% of cases. This commercial TBA should not be used alone as a screening method nor as a confirmatory technique for NSAbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.